Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy

European Heart Journal, Supplement

Volumn 3, Issue L, 2001, Pages

  Sigwart, Ulrich ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Catheter intervention; Hypertrophic obstructive cardiomyopathy; Percutaneous myocardial ablation; Ventricular remodelling

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

ARTICLE; ARTIFICIAL HEART PACEMAKER; BALLOON CATHETER; CARDIOMYOPATHY; CATHETER ABLATION; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035157846     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90063-X     Document Type: Article

References (40)

1. Genes and disease expression in hypertrophic cardiomyopathy
2. Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy
3. Hypertrophic cardiomyopathy: Clinical spectrum and treatment
4. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy
5. Sudden death from cardiac causes in children and young adults
6. Induction of subaortic ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy
7. The management of hypertrophic cardiomyopathy
8. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgement?
9. Hypertrophic obstructive cardiomyopathy: Surgical treatment
10. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy
11. Surgical management of hypertrophic obstructive cardiomyopathy: Early and late results
12. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus
13. Pitfalls in clinical recognition and a novel operative approach for hypertrophic obstructive cardiomyopathy with severe obstruction due to anomalous papillary muscle
14. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy
15. Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: Acute results and 3-month followup in 25 patients
16. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute and 3-months follow-up results with respect to myocardial contrast echocardiography
17. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography
18. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area
19. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy
20. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort
21. Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: A case report
22. Catheter treatment of hypertrophic obstructive cardiomyopathy
23. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy
24. Ongoing clinical and noninvasive improvement after percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)
25. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients
26. Hypertrophic obstructive cardiomyopathy: Alternative therapeutic options
27. Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cradiomyopathy
28. Early results of alcohol ablation of the septal branch of coronary artery in patients with hypertrophic obstructive cardiomyopathy
29. Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy
30. Age related acute results in percutaneous septal ablation in hypertrophic obstructive cardiomyopathy
31. Non-surgical septal ablation (PTSMA) in patients with NYHA class IV and hypertrophic obstructive cardiomyopathy (HOCM)
32. Transcoronary ablation of septal hypertrophy: A new treatment for hypertrophic obstructive cardiomyopathy
33. Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction
34. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Long-term follow-up of the early patients
35. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy
36. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients
37. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
38. Percutaneous septal ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity
39. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment
40. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy